Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2026
[Efficacy of choline alfoscerate treatment for subjective cognitive impairment in first-degree relatives of patients with Alzheimer's disease: Results of a comparative 5-year study].
СтатьяСравнительное исследованиеАннотация на английскомНазвание и аннотация: Оригинал на русском
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Selezneva N D, Roshchina I F, Gavrilova S I
Аннотация
OBJECTIVE: To evaluate the five-year change of cognitive functioning in first-degree relatives of patients with Alzheimer's disease (AD) with signs of subjective cognitive impairment (SCI) treated with choline alfoscerate and untreated.
MATERIAL AND METHODS: The study included 122 subjects: 56 (45.9%) in the treatment group and 66 (54.1%) in the control group. Relatives from the treatment group received 4 courses of three-month oral choline alfoscerate therapy (400 mg 3 times a day) every 1.5 years. The study used prospective clinical, psychometric, neuropsychological, and statistical methods. Evaluation included 9 assessment visits using a battery of 10 cognitive scales and tests: in the treatment group, before and after each course of therapy, with a follow-up assessment 3 months after the end of therapy. Assessment visits in the control group were conducted using a similar methodology at the same time points.
RESULTS: On the Clinical Global Impression (CGI-I) scale, varying improvement was observed in the treatment group after each course of therapy and at follow-up examination. By the end of treatment, 96.8% of the subjects reported a marked and moderate improvement. In the control group, after 57 months, deterioration in cognitive functioning was identified at the 39th, 57th, and 60th months. SCI was converted to mild cognitive impairment syndrome (MCI) in 9.1, 15.2, and 16.7% of cases, respectively. In the treatment group, all psychometric scales and tests showed a significant improvement compared to all baseline mean group indicators after each course of therapy, and at follow-up examination in 4 out of 10 tests. In the control group, significant deterioration in scores on all scales and tests was observed from Month 39 of follow-up.
CONCLUSION: Repeated courses every three months of oral choline alfoscerate therapy for five years led in the vast majority of observations to improved cognitive functioning in persons from the treatment group at increased risk for developing AD, while untreated relatives had decreasing cognitive functioning, including a 16.7% rate of transformation of SCI into MCI.
MATERIAL AND METHODS: The study included 122 subjects: 56 (45.9%) in the treatment group and 66 (54.1%) in the control group. Relatives from the treatment group received 4 courses of three-month oral choline alfoscerate therapy (400 mg 3 times a day) every 1.5 years. The study used prospective clinical, psychometric, neuropsychological, and statistical methods. Evaluation included 9 assessment visits using a battery of 10 cognitive scales and tests: in the treatment group, before and after each course of therapy, with a follow-up assessment 3 months after the end of therapy. Assessment visits in the control group were conducted using a similar methodology at the same time points.
RESULTS: On the Clinical Global Impression (CGI-I) scale, varying improvement was observed in the treatment group after each course of therapy and at follow-up examination. By the end of treatment, 96.8% of the subjects reported a marked and moderate improvement. In the control group, after 57 months, deterioration in cognitive functioning was identified at the 39th, 57th, and 60th months. SCI was converted to mild cognitive impairment syndrome (MCI) in 9.1, 15.2, and 16.7% of cases, respectively. In the treatment group, all psychometric scales and tests showed a significant improvement compared to all baseline mean group indicators after each course of therapy, and at follow-up examination in 4 out of 10 tests. In the control group, significant deterioration in scores on all scales and tests was observed from Month 39 of follow-up.
CONCLUSION: Repeated courses every three months of oral choline alfoscerate therapy for five years led in the vast majority of observations to improved cognitive functioning in persons from the treatment group at increased risk for developing AD, while untreated relatives had decreasing cognitive functioning, including a 16.7% rate of transformation of SCI into MCI.